Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient

Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/D...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakai, Mayu, Takao, Ken, Kato, Takehiro, Ito, Kodai, Kubota, Sodai, Hirose, Tokuyuki, Liu, Yanyan, Mizuno, Masami, Hirota, Takuo, Suwa, Tetsuya, Horikawa, Yukio, Yabe, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177353/
https://www.ncbi.nlm.nih.gov/pubmed/35569928
http://dx.doi.org/10.2169/internalmedicine.9231-21
_version_ 1784722869353185280
author Sakai, Mayu
Takao, Ken
Kato, Takehiro
Ito, Kodai
Kubota, Sodai
Hirose, Tokuyuki
Liu, Yanyan
Mizuno, Masami
Hirota, Takuo
Suwa, Tetsuya
Horikawa, Yukio
Yabe, Daisuke
author_facet Sakai, Mayu
Takao, Ken
Kato, Takehiro
Ito, Kodai
Kubota, Sodai
Hirose, Tokuyuki
Liu, Yanyan
Mizuno, Masami
Hirota, Takuo
Suwa, Tetsuya
Horikawa, Yukio
Yabe, Daisuke
author_sort Sakai, Mayu
collection PubMed
description Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate.
format Online
Article
Text
id pubmed-9177353
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-91773532022-07-05 Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient Sakai, Mayu Takao, Ken Kato, Takehiro Ito, Kodai Kubota, Sodai Hirose, Tokuyuki Liu, Yanyan Mizuno, Masami Hirota, Takuo Suwa, Tetsuya Horikawa, Yukio Yabe, Daisuke Intern Med Case Report Although there is a great demand for increased coronavirus disease 2019 (COVID-19) vaccination worldwide, rare side effects of the vaccine in susceptible individuals are attracting attention. We recently treated a patient with type 1 diabetes who had HLA-A*240201/A*020101, B*5401/B*5601, DRB1*0405/DRB1*0405, DPB1*0501/DPB1*0501 and DQB1*0401/DQB1*040 and developed Graves' disease soon after the administration of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. While causal relationships between vaccinations and adverse events are difficult to discern due to both confounding and masking factors, our findings suggest that attention to possible adjuvant-related endocrinological diseases in certain individuals receiving SARS-CoV-2 vaccines is appropriate. The Japanese Society of Internal Medicine 2022-05-15 2022-05-15 /pmc/articles/PMC9177353/ /pubmed/35569928 http://dx.doi.org/10.2169/internalmedicine.9231-21 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sakai, Mayu
Takao, Ken
Kato, Takehiro
Ito, Kodai
Kubota, Sodai
Hirose, Tokuyuki
Liu, Yanyan
Mizuno, Masami
Hirota, Takuo
Suwa, Tetsuya
Horikawa, Yukio
Yabe, Daisuke
Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title_full Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title_fullStr Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title_full_unstemmed Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title_short Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient
title_sort graves' disease after administration of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) vaccine in a type 1 diabetes patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177353/
https://www.ncbi.nlm.nih.gov/pubmed/35569928
http://dx.doi.org/10.2169/internalmedicine.9231-21
work_keys_str_mv AT sakaimayu gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT takaoken gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT katotakehiro gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT itokodai gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT kubotasodai gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT hirosetokuyuki gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT liuyanyan gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT mizunomasami gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT hirotatakuo gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT suwatetsuya gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT horikawayukio gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient
AT yabedaisuke gravesdiseaseafteradministrationofsevereacuterespiratorysyndromecoronavirus2sarscov2vaccineinatype1diabetespatient

Ejemplares similares